Arcutis Biotherapeutics announced its Q4 and full year 2025 financial results and provided a business update. The company will present at the TD Cowen 46th Annual Health Care Conference on March 2-4, 2026, in Boston. Arcutis also announced that professional golfer Max Homa has joined its 'Free to Be Me' campaign to raise awareness about seborrheic dermatitis treatments.

Arcutis Biotherapeutics reported Q4 2025 net product revenue of $127.5 million for ZORYVE (roflumilast), an 84% increase year-over-year, with full-year 2025 revenue reaching $372.1 million (123% growth). The company achieved positive operating cash flow, raised 2026 guidance to $480-495 million, and reported positive Phase 2 trial data for pediatric atopic dermatitis. The company is expanding its dermatology sales force and assuming direct responsibility for pediatric and primary care commercialization.

Tejara Capital exited its entire position in Arcutis Biotherapeutics, selling 520,503 shares for approximately $9.81 million in February 2026. The stock has surged 99.1% over the past year, driven by strong Q3 results showing net product revenue more than doubling year-over-year. The fund's exit appears to be risk management after the sharp Q4 rally rather than a bearish signal, as the company maintains confidence in its commercial trajectory with 2026 guidance of $455-470 million in net product sales.

Arcutis Biotherapeutics granted 94,000 restricted stock units to 12 newly hired employees as an inducement for employment. The awards were approved by the Compensation Committee under the 2022 Inducement Plan with a grant date of February 2, 2026, and vest over four years with 25% vesting annually.

Arcutis Biotherapeutics announced it will report Q4 and full year 2025 financial results on February 25, 2026, followed by a conference call at 4:30 p.m. ET. The company will also present at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026. Arcutis highlighted 2026 strategic priorities and announced a nationwide survey addressing concerns about topical steroid use and the need for long-term treatment strategies for chronic inflammatory skin conditions.

A nationwide survey of 1,500 respondents reveals that nearly 9 in 10 adults and parents with chronic inflammatory skin conditions are concerned about topical steroid side effects, and approximately 8 in 10 report their treatment plans focus on reactive flare management rather than proactive long-term disease management. The survey highlights significant emotional and social burdens when skin conditions are uncontrolled, with many patients avoiding social activities and experiencing anxiety.

Suvretta Capital Management sold nearly 1.1 million shares of Arcutis Biotherapeutics (ARQT) during Q3, reducing its position by $35.78 million. Despite the sale, ARQT remains the fund's largest holding worth $197.51 million. The stock has doubled in value over the past year, significantly outperforming the S&P 500. The sale appears to be a risk management decision following the dramatic stock appreciation rather than a loss of conviction in the company's fundamentals.

Arcutis Biotherapeutics is a promising biotech company with its key drug Zoryve, treating inflammatory skin diseases. The company shows strong sales growth, potential peak sales of $2.6-$3.5 billion, and is expanding its drug approvals across multiple indications.

Arcutis Biotherapeutics appointed Amit Munshi to its Board of Directors and announced the retirement of founder Bhaskar Chaudhuri, marking a leadership transition for the biopharmaceutical company.

Arcutis Biotherapeutics has submitted a supplemental New Drug Application to the FDA for ZORYVE cream 0.3%, seeking approval to treat plaque psoriasis in children ages 2 to 5. If approved by the June 29, 2026 target date, it would be the first topical PDE4 inhibitor for this age group.

Arcutis Biotherapeutics granted 51,000 restricted stock units to six newly hired employees, with units vesting over four years and subject to continuous employment.

Arcutis Biotherapeutics will participate in two upcoming investor conferences in November 2025, presenting new data on ZORYVE cream for atopic dermatitis treatment, including FDA approval for children ages 2-5.